Table 1.
Base-case cost (£) of Mab treatments, net monetary benefit, and threshold cost at which the net monetary benefit was 0.
| Base-case annual cost of mabs | Net monetary benefit at base-case annual cost (21) | Threshold cost for net return to turn 0 | |
|---|---|---|---|
| (a) Melanoma | |||
| Ipilimumab | 75,000 | −25,597,604 | 48,532 (35% discount) |
| Nivolumab | 36,335 | 5,083,681 | 144,324 (297% increase) |
| Ipi-nivo | 127,660 | 11,239,145 | 153,294 (20% increase) |
| Pembrolizumab (22) | 118,525 | −10,394,459 | 105,594 (11% discount) |
| (b) Rheumatoid arthritis | |||
| Adalimumab (pre-2019) | 9,156 | 3,033,193,847 | 14,469 (58% increase) |
| Adalimumab (post-2019) | 3,679 | 3,033,193,847 | 27,166 (638% increase) |
The table is reformatted from Supplementary Tables S4, S5.